Missouri Judge Approves Bayer’s $7.25bn Roundup Cancer Settlement

A Missouri judge has approved Bayer’s $7.25 billion settlement aimed at resolving tens of thousands of lawsuits alleging that its Roundup weedkiller caused cancer, marking a major development in the German company’s long-running legal battle in the United States.

Judge Timothy Boyer of a state court in St. Louis ruled on Friday that the agreement was “fair, reasonable and adequate”, rejecting objections from some claimants who argued that the proposed compensation was insufficient.

Bayer had faced approximately 65,000 claims from people who said they developed cancer after using Roundup at home or at work. The settlement, announced in February 2026, is intended to resolve nearly all existing and future US claims involving the weedkiller. 

Judge rejects objections over compensation

Some claimants and their lawyers opposed the agreement, arguing that the proposed payouts were too low compared with compensation received by people who had previously settled their cases.

However, Judge Boyer rejected those objections, warning that further delays could leave seriously ill claimants, including people with terminal cancer, waiting an indefinite number of years for compensation.

The settlement provides for payments of up to $7.25 billion over a period of as long as 21 years. Individual compensation will depend on factors such as the claimant’s age, medical condition and exposure to Roundup.

Bayer company logo representing the German group involved in the Roundup settlement.
German pharmaceutical and chemicals group Bayer has secured court approval for its proposed Roundup litigation settlement.

Supreme Court ruling strengthened Bayer’s legal position

The approval comes after a significant legal victory for Bayer at the US Supreme Court in June 2026.

The court overturned a $1.25 million jury award to a Missouri man who blamed exposure to Roundup’s active ingredient, glyphosate, for his non-Hodgkin lymphoma.

In its decision, the Supreme Court found that federal pesticide regulations barred certain state-level claims that Bayer had failed to provide adequate cancer warnings on the product’s label. The ruling weakened a central argument used in many lawsuits against the company.

Bayer continues to deny Roundup causes cancer

Bayer has consistently maintained that Roundup and its active ingredient, glyphosate, are safe and that decades of research do not establish that the weedkiller causes cancer.

The company acquired Monsanto, Roundup’s manufacturer, in 2018 for approximately $63 billion. Since then, the litigation has imposed substantial financial and legal pressure on the business.

Bayer previously paid about $10.9 billion in 2020 to resolve many existing Roundup lawsuits, but efforts to secure approval for a separate settlement covering future claims were unsuccessful.

Chief Executive Bill Anderson described the latest approval as a major step towards reducing the company’s exposure to pending and future litigation. 

Courthouse in Missouri where the Bayer Roundup settlement received judicial approval.
A Missouri judge has approved Bayer’s $7.25 billion agreement to settle most current and future US Roundup cancer claims. Photo: Missouri Independent

Some lawsuits remain outside the settlement

Despite the approval, the agreement does not cover every pending Roundup case. Bayer said approximately 200 lawsuits consolidated in federal court remain unresolved and that the Supreme Court’s decision has strengthened its defence in those proceedings.

The settlement could significantly reduce the number of legal disputes facing Bayer, although its full implementation remains subject to any further legal challenges.


Discover more from LN247

Subscribe to get the latest posts sent to your email.

Advertisement

Most Popular This Week

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Related Posts

Advertisement